The exogenous route is essential for producing CD8+ CTL responses, especially for tumour antigens and therefore improved cross-presentation of exogenous antigens is considered an invaluable tactic for effective cancer immunotherapy [17]. This evidence concerns the gene CD8A and neoplasm.